Status: Recruiting
Study of XmAb412 in Healthy Participants
This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants
Participants needed: 128
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Xencor, Inc.Updated: Aug 3, 2026Locations: 2
Eligibility criteria
Age 18-55 years old [+4]
Any physical condition that prohibits study completion [+6]